<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511250</url>
  </required_header>
  <id_info>
    <org_study_id>INV-DEN-203</org_study_id>
    <nct_id>NCT01511250</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of a dengue vaccine
      administered subcutaneously in healthy adults and children. In addition the antibody
      response to the four dengue virus serotypes will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Injection site reactions to a dengue vaccine administered subcutaneously</measure>
    <time_frame>30 days post dose</time_frame>
    <description>Local injection site reactions that measure erythema (rash), edema, pain and itching will be evaluated. Active vaccine will be compared to placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic reactions to a dengue vaccine administered subcutaneously</measure>
    <time_frame>up to Day 120</time_frame>
    <description>Systemic reactions, including fever and rash, will be evaluated in subjects receiving dengue vaccine and compared to subjects receiving placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody titers of a dengue vaccine against four serotypes of dengue virus</measure>
    <time_frame>30 days post dose 2</time_frame>
    <description>Neutralizing antibody titers (at Day 120) will be compared to baseline (day 0) titers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Phosphate buffered saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate buffered saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DENVax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Live attenuated experimental Dengue vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DENVax</intervention_name>
    <description>live attenuated Dengue vaccine, 0.5 ml dose subcutaneously administered at Day 0 and Day 90</description>
    <arm_group_label>DENVax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Phosphate buffered saline</intervention_name>
    <description>placebo control</description>
    <arm_group_label>Phosphate buffered saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health

          -  Normal laboratory values at screening

        Exclusion Criteria:

          -  Abnormal ECG

          -  History of significant dermatologic (skin) disease within last 6 months

          -  Diabetes mellitus

          -  History of any immunodeficiency

          -  History of recurring headaches or migraines

          -  Hypersensitivity to vaccines

          -  Use of amphetamines, opiates, cannabinoids

          -  History of alcohol abuse

          -  Pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilad Gordon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Inviragen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad de Antiquia, PECET</name>
      <address>
        <city>Medillin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine, CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latin Clinical Trial Center</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, School of Medicine</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital, Department of Pediatrics</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital 2</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 29, 2016</lastchanged_date>
  <firstreceived_date>November 16, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>November 29, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>normal healthy adults and children</keyword>
  <keyword>Safety and tolerability</keyword>
  <keyword>active vaccine</keyword>
  <keyword>placebo</keyword>
  <keyword>Dengue virus vaccine</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
